Article
20 Jul 2026
Cour suprême du Canada : les méthodes de traitement médical demeurent non brevetables, mais la validité du brevet de Janssen sur un schéma posologique de palipéridone est confirmée
AUTHORS CONTENT
Article
20 Jul 2026
Supreme Court Of Canada: Methods Of Medical Treatment Unpatentable, Validity Of Janssen’s Paliperidone Dosing Regimen Patent Upheld
Article
22 Jan 2026
Revue de l'année 2025 en droit des brevets au Canada
Article
21 Jan 2026
Canadian Patent Law 2025: A Year In Review
Article
18 Nov 2025
La Cour suprême du Canada a mis en délibéré son jugement dans le cadre de l'appel relatif à la brevetabilité des méthodes de traitement médical
Article
13 Oct 2025
Supreme Court Of Canada Reserves Decision On Appeal Relating To The Patentability Of Methods Of Medical Treatment
Article
04 Jun 2024
Federal Court Of Appeal Upholds Invalidity Of Lilly's CIALIS Patent Extending To "Physiologically Acceptable Salt"
Article
02 Feb 2024
LUMIGAN RC Formulation Patent Found Valid And Infringed
Article
01 Mar 2023
Lilly's CIALIS Patent Claims Extending To "physiologically Acceptable Salt" Found Invalid For Overbreadth And Insufficiency
Article
31 Aug 2022
Federal Court Of Appeal Upholds Invalidity Of Fampridine Patent
Article
30 May 2022
Supreme Court Of Canada Denies Merck Leave To Appeal From Decision Upholding Strict Interpretation Of Patent Listing Deadline
Article
29 Apr 2022
Merck's JANUVIA Crystalline Monohydrate DHP Salt Patent Found Valid
Article
02 Feb 2022
Federal Court Of Appeal Upholds Validity Of Glatiramer Acetate Patent
Article
02 Dec 2021
Federal Court Of Appeal Dismisses Appeal, Upholds Strict Interpretation Of Patent Listing Deadline For KEYTRUDA Formulation Patent
Article
04 Nov 2021
Supreme Court Of Canada Denies Leave Regarding Lisdexamfetamine Patent Decision
Article
16 Jul 2021
Apotex Seeks Leave To Appeal Lisdexamfetamine Patent Decision
Article
02 Jul 2021
Federal Court Of Appeal Finds Summary Trial Appropriate, Upholds Dismissal Of ViiV's Action For Patent Infringement Re: Gilead's BIKTARVY
Article
04 May 2021
Federal Court Upholds Health Canada's Strict Interpretation Of Patent Listing Deadline For KEYTRUDA Formulation Patent
Article
05 Apr 2021
Federal Court Of Appeal Upholds Federal Court Decision Finding Shire's VYVANSE Patent Valid
Article
01 Oct 2020
Federal Court Of Appeal Refuses To Grant Stay Of Federal Court Decision Remanding Health Canada's Refusal Of SHINGRIX CSP